TY - JOUR
T1 - Intranasal corticosteroid therapy in the treatment of obstructive sleep apnea
T2 - A meta-analysis of randomized controlled trials
AU - Liu, Hsien Ta
AU - Lin, Ying Chin
AU - Kuan, Yi Chun
AU - Huang, Yao Hsien
AU - Hou, Wen Hsuan
AU - Liou, Tsan Hon
AU - Chen, Hung Chou
N1 - Publisher Copyright:
© 2016, OceanSide Publications, Inc., U.S.A.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Aim: To assess the efficacy of intranasal corticosteroid therapy in the treatment of obstructive sleep apnea (OSA) based on current evidence. Methods: A number of medical literature data bases: PubMed, Cochrane Library, Scopus, and CINAHL, were searched comprehensively to identify randomized controlled trials (RCT) that reported on the efficacy of intranasal corticosteroid therapy for OSA. The selected studies were subjected to a meta-analysis and a risk-of-bias assessment. Results: Seven RCTs met our eligibility criteria, five of these were included in our meta-analysis. The results indicated that intranasal corticosteroid therapy has a better effect in decreasing the apnea-hypopnea index compared with those participants who received placebo (standard mean difference 0.95 [95% confidence interval, -1.42 to -0.47]) (n - 221, I2 = 62%). Conclusion: Our study results showed that patients who received intranasal corticosteroid therapy had a significant improvement in OSA. However, this evidence was limited by the potential risk of bias and heterogeneity of the selected RCTs.
AB - Aim: To assess the efficacy of intranasal corticosteroid therapy in the treatment of obstructive sleep apnea (OSA) based on current evidence. Methods: A number of medical literature data bases: PubMed, Cochrane Library, Scopus, and CINAHL, were searched comprehensively to identify randomized controlled trials (RCT) that reported on the efficacy of intranasal corticosteroid therapy for OSA. The selected studies were subjected to a meta-analysis and a risk-of-bias assessment. Results: Seven RCTs met our eligibility criteria, five of these were included in our meta-analysis. The results indicated that intranasal corticosteroid therapy has a better effect in decreasing the apnea-hypopnea index compared with those participants who received placebo (standard mean difference 0.95 [95% confidence interval, -1.42 to -0.47]) (n - 221, I2 = 62%). Conclusion: Our study results showed that patients who received intranasal corticosteroid therapy had a significant improvement in OSA. However, this evidence was limited by the potential risk of bias and heterogeneity of the selected RCTs.
UR - http://www.scopus.com/inward/record.url?scp=84971638520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84971638520&partnerID=8YFLogxK
U2 - 10.2500/ajra.2016.30.4305
DO - 10.2500/ajra.2016.30.4305
M3 - Article
C2 - 27216353
AN - SCOPUS:84971638520
SN - 1945-8924
VL - 30
SP - 215
EP - 221
JO - American Journal of Rhinology and Allergy
JF - American Journal of Rhinology and Allergy
IS - 3
ER -